Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service SI joint fusion cases in Idaho: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 16% on average (37 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 0 | 17 | 37% |
| 2020 | 0 | 33 | 40% |
| 2021 | 0 | 20 | 43% |
| 2022 | 1 | 40 | 47% |
| 2023 | 1 | 50 | 50% |
| 2024 | 2 | 102 | 52% |
| 2025 from claims | – | 89 72–104 | 54% |
| 2026 forecast | – | 107 83–134 | 49% |
| 2027 forecast | – | 119 88–157 | 49% |
| 2028 forecast | – | 133 94–183 | 49% |
| 2029 forecast | – | 148 101–213 | 49% |
| 2030 forecast | – | 166 108–246 | 48% |
Minimally invasive and open sacroiliac joint fusion. Professional codes (what the surgeon bills): CPT 27279, 27280, 0775T, 27278.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Idaho; 2 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 51% inpatient hospital, 49% hospital outpatient.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 23 | 583+5.4%/yr | +5.4%/yr | 0.2 | 32% | 500 in 2030−2.5%/yr |
| Arizona | 5 | 365+24%/yr | +24%/yr | 0.4 | 67% | 950 in 2030+17%/yr |
| Colorado | 9 | 330+20%/yr | +20%/yr | 0.6 | 11% | 570 in 2030+9.4%/yr |
| Washington | 4 | 187−0.2%/yr | −0.2%/yr | 0.2 | 100% | 80 in 2030−12%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Lumbar fusion | 21 | 882+2.3%/yr | +2.3%/yr | 4.21.5× | 2% | 1,290 in 2030+6.6%/yr |
| Decompression & minimally invasive spine | 23 | 876−1.5%/yr | −1.5%/yr | 4.21.3× | 1% | 1,130 in 2030+4.3%/yr |
| Cervical fusion & disc arthroplasty | 8 | 341−3.9%/yr | −3.9%/yr | 1.61.3× | 0% | 450 in 2030+4.8%/yr |
| Kyphoplasty & vertebroplasty | 3 | 261−4.7%/yr | −4.7%/yr | 1.31.4× | 0% | 490 in 2030+11%/yr |
SI joint fusion in every state, and its device makers · Every procedure market in Idaho · Every state · Compare with California
SI-BONE leads with 83% of company spending on these surgeons in 2025, −16 pts on 2024.
In 2025, 4 companies reported engagement with Idaho’s surgeons worth $30K in consulting, speaking, meals and travel tied to these products, about $15K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 7 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.